Active exits MidEuropa has a track record of significant exits and asset sales, including recent actions like selling assets to Mehiläinen Group and EssilorLuxottica, as well as notable IPO activity. This indicates readiness to monetize portfolio positions and potential for co-investment opportunities with buyers attracted to MidEuropa’s deal flow.

Healthcare cadence A notable portion of MidEuropa’s activity centers on healthcare and medical technologies, including exits linked to ophthalmic clinics and healthcare services transactions. This suggests strong interest from strategic buyers in healthcare platforms and potential deal sourcing for healthtech and service providers.

Regional depth With roots in Central Europe and offices in London, Warsaw, and Bucharest, MidEuropa combines regional expertise with cross-border capability, making it a prime partner for vendors seeking pan-Central European expansion or exit strategies that leverage multi-country footprints.

Fundraising momentum Having raised and managed funds of over €6.8 billion and completed dozens of investments and add-ons across many countries, MidEuropa signals strong financial backing and a capacity to support sizable, multi-phase transactions that may interest large strategic or financial buyers.

Portfolio signals Recent activity includes acquisitions of Famar and MBL Group and a history of CDMO and diagnostic/healthcare assets, indicating a portfolio shift toward science-based services and manufacturing. This presents opportunities for strategic buyers in life sciences infrastructure, contract development, and expansion-focused vendors seeking exit or growth capital.